--- title: "Aptevo Therapeutics (APVO) news: reverse split and going concern" url: "https://aibio.space/companies/aptevo-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "APVO reverse split, going concern and offering news: Aptevo Therapeutics gets Nasdaq stockholders' equity notice, sets 1-for-20 reverse stock split." --- APVO Aptevo Therapeutics Inc. NASDAQ · United States # Aptevo Therapeutics (APVO) news APVO reverse split, going concern and offering news Company Updates · 2026-10-26 ## [Aptevo says ten frontline AML patients on mipletamig reached stem cell transplant](https://aibio.space/news/aptevo-says-ten-frontline-aml-patients-mipletamig-reached-stem-cell/) Ten patients with newly diagnosed AML advanced to transplant after treatment with mipletamig, venetoclax and azacitidine, according to Aptevo's October 26, 2026 release. ## Latest Aptevo Therapeutics news 1. 2026-10-14 Company Updates [Aptevo to present CD40 multispecific platform data at SITC 2026](https://aibio.space/news/aptevo-present-cd40-multispecific-platform-data-sitc-2026/) Aptevo will present its CD40-directed multispecific portfolio at the Society for Immunotherapy of Cancer annual meeting in Phoenix, November 4 to 8, 2026. 2. 2026-09-24 Company Updates [Aptevo advances trispecific candidates toward scalable manufacturing](https://aibio.space/news/aptevo-advances-trispecific-candidates-toward-scalable-manufacturing/) Aptevo is optimizing several trispecific candidates for scalable manufacturing and expects IND-enabling studies for its lead candidate, APVO451, in the first half of 2027. 3. 2026-09-03 Company Updates [Aptevo reports 93% clinical benefit rate with mipletamig in TP53-mutated AML](https://aibio.space/news/aptevo-reports-93-percent-clinical-benefit-rate-mipletamig-tp53/) Thirteen of 14 evaluable TP53-mutated frontline AML patients treated with mipletamig, venetoclax and azacitidine had clinical benefit, according to Aptevo's September 3, 2026 release. 4. 2026-08-13 Financings [Aptevo Therapeutics closes warrant inducement and private placement for about $4.5 million](https://aibio.space/news/aptevo-therapeutics-closes-warrant-inducement-private-placement-about/) Aptevo Therapeutics (Nasdaq: APVO) closed deals that cut warrant exercise prices to $4.03 per share and sold shares or pre-funded warrants in a private placement. Roth Capital Partners was placement agent. 5. 2026-07-27 Company Updates [Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone](https://aibio.space/news/aptevo-files-patent-application-nectin-4-x-pd-l1-dual-targeting/) Aptevo filed a patent application covering a Nectin-4 x PD-L1 dual-targeting backbone that it says could support radiopharmaceuticals, T-cell engagers and other immune-based approaches. 6. 2026-06-30 Company Updates [Aptevo receives $1.5 million grant to advance APVO451](https://aibio.space/news/aptevo-receives-1-5-million-grant-advance-apvo451/) Aptevo was awarded a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling work for APVO451, its nectin-4-targeted trispecific candidate. 7. 2026-05-27 Financings [Aptevo and Niowave launch 50/50 radiopharmaceutical collaboration](https://aibio.space/news/aptevo-niowave-launch-50-50-radiopharmaceutical-collaboration/) Aptevo and Niowave agreed to a 50/50 collaboration to develop up to three radiopharmaceutical oncology programs, with Niowave making an at-the-market equity investment at closing. 8. 2026-05-13 Company Updates [Aptevo completes CEO transition and secures $60 million equity line](https://aibio.space/news/aptevo-completes-ceo-transition-secures-60-million-equity-line/) Aptevo says its RAINIER trial of mipletamig remains on track for Phase 2 dose selection by year end, and that a $60 million standby equity purchase agreement extends its access to capital. 9. 2026-05-06 Company Updates [Aptevo reports 87% clinical benefit in frontline AML through Cohort 5](https://aibio.space/news/aptevo-reports-87-percent-clinical-benefit-frontline-aml-through/) Aptevo says mipletamig data from 31 evaluable frontline AML patients show continued activity, and that the RAINIER trial has entered its final dose-optimization stage. 10. 2025-06-30 Listings [Aptevo says $15.9 million in new equity puts it back in line with Nasdaq rule](https://aibio.space/news/aptevo-says-15-9-million-new-equity-puts-back-line-nasdaq-rule/) Aptevo says about $15.9 million of gross equity raised in the June quarter puts it back above Nasdaq's $2.5 million stockholders' equity minimum. The figure is the company's own belief, and it was still awaiting formal confirmation from Nasdaq. 11. 2025-06-16 Financings [Aptevo files stock and warrant offering, signs $25.0 million Yorkville equity line](https://aibio.space/news/aptevo-files-stock-warrant-offering-signs-25-0-million-yorkville/) Aptevo filed to sell up to 1,709,401 shares with five common warrants each and signed a $25.0 million equity line with Yorkville. Its auditor's report carries a going concern paragraph, and cash was $2,139 thousand at March 31, 2025. 12. 2025-05-22 Listings [Aptevo Therapeutics gets Nasdaq stockholders' equity notice, sets 1-for-20 reverse stock split](https://aibio.space/news/aptevo-therapeutics-gets-nasdaq-stockholders-equity-notice-sets-1-20/) Aptevo reported a stockholders' deficit of $1,473,000 against a $2,500,000 minimum. It also filed an at-the-market prospectus supplement for up to $3,015,515 of stock, and it set a 1-for-20 reverse stock split for May 23, 2025. ## Aptevo Therapeutics at a glance - **Ticker**: APVO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.8 million ### Related companies - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX - [Kura Oncology](https://aibio.space/companies/kura-oncology/) NASDAQ: KURA - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) NASDAQ: CBIO - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) NASDAQ: CADL - [Neurogene](https://aibio.space/companies/neurogene/) NASDAQ: NGNE - [Nuvation Bio](https://aibio.space/companies/nuvation-bio/) NYSE: NUVB - [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON ### Also on NASDAQ - [Tenon Medical](https://aibio.space/companies/tenon-medical/) TNON - [Nutriband](https://aibio.space/companies/nutriband/) NTRB - [UTAH MEDICAL PRODUCTS INC](https://aibio.space/companies/utah-medical-products/) UTMD - [BioStem Technologies](https://aibio.space/companies/biostem-technologies/) BSEM - [Anixa Biosciences](https://aibio.space/companies/anixa-biosciences/) ANIX - [Korsana Biosciences](https://aibio.space/companies/korsana-biosciences/) KRSA ## What Aptevo Therapeutics does Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company developing novel immunotherapy candidates for different forms of cancer. Its two platform technologies, ADAPTIR and ADAPTIR-FLEX, are used to design monospecific and multi-specific antibody candidates that engage immune cells against tumors, and the company says it wholly owns both platforms. It has two clinical candidates and six preclinical candidates. The lead blood cancer candidate, mipletamig, is a CD123xCD3 T cell engager in the RAINIER trial, a Phase 1b/2 program initiated in August 2024 in frontline acute myelogenous leukemia in combination with venetoclax and azacitidine. The lead solid tumor candidate, ALG.APV-527, targets 4-1BB and 5T4 and was developed in partnership with Alligator Bioscience AB. In its dose escalation trial, 58% of nineteen patients achieved a best response of stable disease. The company says it is being evaluated for multiple solid tumor types, potentially including breast, cervical, non-small-cell lung, prostate, renal, gastric, colorectal and bladder cancers. | Product or program | What it is | Stage | |---|---|---| | Mipletamig | CD123xCD3 T cell engager for frontline acute myelogenous leukemia | Phase 1b/2 RAINIER trial initiated August 2024 | | ALG.APV-527 | Antibody targeting 4-1BB and 5T4 for multiple solid tumor types | clinical candidate; dose escalation trial reported | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm). ## Aptevo Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$14.5 million](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/) | [$14.4 million](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/) | | Net income (loss) | [-$26.0 million](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/) | [-$24.1 million](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/) | | Cash from operations | [-$25.6 million](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/) | [-$23.8 million](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/) | | Cash and equivalents | [$21.6 million](https://www.sec.gov/Archives/edgar/data/1671584/000119312526350559/) | [$8.7 million](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Aptevo Therapeutics Did Aptevo Therapeutics do a reverse stock split? Our latest story on this, dated May 22, 2025: "Aptevo Therapeutics gets Nasdaq stockholders' equity notice, sets 1-for-20 reverse stock split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aptevo-therapeutics-gets-nasdaq-stockholders-equity-notice-sets-1-20/). Has Aptevo Therapeutics issued a going-concern warning? Our latest story on this, dated Jun 16, 2025: "Aptevo files stock and warrant offering, signs $25.0 million Yorkville equity line". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aptevo-files-stock-warrant-offering-signs-25-0-million-yorkville/). Has Aptevo Therapeutics raised money recently? Our latest story on this, dated Aug 13, 2026: "Aptevo Therapeutics closes warrant inducement and private placement for about $4.5 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aptevo-therapeutics-closes-warrant-inducement-private-placement-about/). What is the ticker symbol of Aptevo Therapeutics? Aptevo Therapeutics Inc. trades under the ticker APVO on NASDAQ. Where is Aptevo Therapeutics listed? Aptevo Therapeutics Inc. is listed on NASDAQ. What is the SEC CIK of Aptevo Therapeutics? The SEC Central Index Key (CIK) for Aptevo Therapeutics Inc. is 1671584. Its filings are on SEC EDGAR. How many shares does Aptevo Therapeutics have outstanding? 1,801,970 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Aptevo Therapeutics listed under? Our directory records Aptevo Therapeutics Inc. under United States. What does Aptevo Therapeutics do? Our directory classifies Aptevo Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Aptevo Therapeutics? The ISIN recorded for Aptevo Therapeutics Inc. is US03835L7029. Does aibio.space cover Aptevo Therapeutics? aibio.space lists Aptevo Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Aptevo Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Aptevo Therapeutics develop? Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company developing novel immunotherapy candidates for different forms of cancer. Its two platform technologies, ADAPTIR and ADAPTIR-FLEX, are used to design monospecific and multi-specific antibody candidates that engage immune cells against tumors, and the company says it wholly owns both platforms. What is Mipletamig from Aptevo Therapeutics? Mipletamig: CD123xCD3 T cell engager for frontline acute myelogenous leukemia Stage: Phase 1b/2 RAINIER trial initiated August 2024. What is ALG.APV-527 from Aptevo Therapeutics? ALG.APV-527: Antibody targeting 4-1BB and 5T4 for multiple solid tumor types Stage: clinical candidate; dose escalation trial reported. ## Investor discussion: Aptevo Therapeutics Members talk about Aptevo Therapeutics (APVO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Aptevo Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-30 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000119312526441770/apvo-2026-atm_sticker.htm) 2. 2026-03-26 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126278/apvo-20251231.htm) 3. 2026-01-30 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000119312526032011/apvo-2026-424b4_-_eloc.htm) 4. 2026-01-09 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000119312526008318/apvo-ex99_1.htm) 5. 2025-12-29 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000119312525335497/apvo-20251229.htm) 6. 2025-11-25 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000119312525297513/apvo-2025-424b4_-_eloc2.htm) 7. 2025-08-08 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025105823/apvo-2025-424b4_-_eloc.htm) 8. 2025-07-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025098429/apvo-20250724.htm) 9. 2025-07-03 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025093924/apvo-20250702.htm) 10. 2025-06-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025091581/apvo-20250630.htm) 11. 2025-06-23 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025088970/apvo-20250623.htm) 12. 2025-06-23 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025089090/apvo-20250623.htm) 13. 2025-06-16 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025086548/apvo-2025-s1_-_june_offe.htm) 14. 2025-05-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025077089/apvo-20250523.htm) 15. 2025-05-22 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025076336/apvo-2025_-_atm_sticker_.htm) 16. 2025-05-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025076482/apvo-ex99_1.htm) 17. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025058694/apvo-2025-def14a_-_smpro.htm) 18. 2025-04-10 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025052922/apvo-2025-pre14a_-_proxy.htm) 19. 2025-03-03 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017025030286/apvo-2025-s1_-_march_off.htm) 20. 2024-12-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017024135890/apvo-20241212.htm) 21. 2024-12-03 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1671584/000095017024132855/apvo-20241203.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:APVO on TradingView](https://www.tradingview.com/symbols/NASDAQ-APVO/). ## SEC filings and registration - **SEC name**: Aptevo Therapeutics Inc. - **CIK**: 1671584 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: APVO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2401 4TH AVE., SEATTLE, WA, 98121 - **Phone**: 206-838-0500 - **Shares outstanding**: 1,801,970 as of 2026-08-14 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1671584/000119312526421076/apvo-20261014.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1671584/000119312526400213/apvo-20260924.htm) filed 2026-09-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1671584/000119312526399545/apvo-20260922.htm) filed 2026-09-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1671584/000119312526381098/apvo-20260903.htm) filed 2026-09-03 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1671584/000119312526376763/apvo-20260831.htm) filed 2026-08-31 - [S-1](https://www.sec.gov/Archives/edgar/data/1671584/000119312526361103/apvo-20260821.htm) filed 2026-08-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1671584/000119312526361079/apvo-20260821.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1671584/000119312526350559/apvo-20260630.htm) filed 2026-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001671584), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Aptevo Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker APVO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Aptevo Therapeutics Inc. - **Ticker**: APVO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US03835L7029 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-APVO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/aptevo-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aptevo Therapeutics (APVO) news: reverse split and going concern", 2026-10-31, https://aibio.space/companies/aptevo-therapeutics/